Mazdutide 10mg

1. What is Mazdutide?

Mazdutide is a synthetic peptide designed as a GLP-1 (glucagon-like peptide-1) receptor agonist, primarily developed for the treatment of obesity and type 2 diabetes. It combines the effects of GLP-1 and a GIP (gastric inhibitory polypeptide) receptor agonist, which work together to improve insulin sensitivity, reduce food intake, and promote weight loss. Mazdutide is studied for its potential to regulate blood glucose levels and support metabolic health.

2. Mazdutide Structure

Molecular Formula：C210H322N46O67

Molecular Weight：4563.1g/mol

CAS Number：2259884-03-0

3. Mazdutide Research

Mazdutide (IBI362 / LY3305677) is a longacting, onceweekly injectable dual agonist that targets both GLP1 receptors (GLP1R) and glucagon receptors (GCGR)—derived from the endogenous peptide oxyntomodulin, with acylation modifications to extend its halflife【https://en.wikipedia.org/wiki/Mazdutide?utm_source=chatgpt.com】.

【1】 Key Phase 3 Results (GLORY1, published in NEJM):

Population: 610 Chinese adults (BMI ≥28 kg/m² or 24–28 kg/m² with comorbidity) 【https://www.prnewswire.com/news-releases/phase-3-clinical-study-of-mazdutide-in-chinese-adults-with-overweight-or-obesity-glory-1-published-in-the-new-england-journal-of-medicine-nejm-302464859.html?utm_source=chatgpt.com】.

Dosing: Onceweekly 4 mg or 6 mg subcutaneously for 48 weeks.

Efficacy:

Week 32: Mean weight loss of −10.97% (4 mg) and −13.38% (6 mg) vs. −0.24% placebo.

Week 48: −12.05% (4 mg) and −14.84% (6 mg) vs. −0.47% placebo 【https://www.prnewswire.com/news-releases/phase-3-clinical-study-of-mazdutide-in-chinese-adults-with-overweight-or-obesity-glory-1-published-in-the-new-england-journal-of-medicine-nejm-302464859.html?utm_source=chatgpt.com】.

≥5% weight reduction: 76.3% (4 mg), 84.0% (6 mg) vs. 10.9% placebo.

≥15% weight reduction: 37.0% (4 mg), 50.6% (6 mg) vs. 2.1% pla【https://www.prnewswire.com/news-releases/phase-3-clinical-study-of-mazdutide-in-chinese-adults-with-overweight-or-obesity-glory-1-published-in-the-new-england-journal-of-medicine-nejm-302464859.html?utm_source=chatgpt.com】.

Metabolic Effects:

Liver fat reduction: −63% (4 mg) and −73% (6 mg) at Week 48 for baseline ≥5% hepatic steatosis 【https://www.prnewswire.com/news-releases/phase-3-clinical-study-of-mazdutide-in-chinese-adults-with-overweight-or-obesity-glory-1-published-in-the-new-england-journal-of-medicine-nejm-302464859.html?utm_source=chatgpt.com】

Improvements in blood pressure, lipids, uric acid, liver enzymes; minimal heart-rate increase (~+2.6 bpm) 【https://www.prnewswire.com/news-releases/phase-3-clinical-study-of-mazdutide-in-chinese-adults-with-overweight-or-obesity-glory-1-published-in-the-new-england-journal-of-medicine-nejm-302464859.html?utm_source=chatgpt.com】

【2】Preclinical & Mechanistic Insights:

In db/db diabetic mice, Mazdutide improved cognition, neuronal structure, and synaptic plasticity more than dulaglutide, with multi-omics revealing enhanced neuroprotective and metabolic pathways 【https://pubmed.ncbi.nlm.nih.gov/40479843/】

The dual-agonist profile enables simultaneous satiety (GLP1R) and thermogenesis & lipid oxidation (GCGR), targeting weight and metabolism synergistically 【https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1309118/full?utm_source=chatgpt.com】.

4. Future Mazdutide Research

【1】Global Phase 3 Trials for T2DM & NAFLD:
– Ongoing DREAMS‑series studies aim to validate Mazdutide’s efficacy in glycemic control and NAFLD/NASH improvement. Early signals show robust HbA1c, weight, and liver enzyme reductions.

【2】 Mechanistic Studies in Energy Balance & CNS Effects:
– Dual GLP‑1/GCGR agonism enhances hepatocyte β-oxidation and whole-body energy expenditure, offering insights into compensating GLP‑1R-associated metabolic shifts.
– Cognitive benefits are being explored in human metabolic-cognitive comorbidities, influenced by animal-detected neuroprotective effects.

【3】Head-to-Head Comparisons & Combinatorial Studies:
– Trials comparing Mazdutide with semaglutide, tirzepatide, and newer tri-agonists (e.g., retatrutide) are underway to frame its efficacy hierarchy.

【4】Extended Formulations & Patient-Centric Delivery:
– Concepts in development include: sustained-release depots, monthly dosing, and self-administration devices to boost adherence.

【5】Broader Indications:
– Emerging trials examining Mazdutide in PCOS, alcohol-use disorder, and cardiovascular disease prevention, leveraging its broad metabolic impact.

5. Application Area

1. Obesity Management:
   – First-in-class dual agonist approved in China (June 2025) for adult overweight/obesity.
   – Delivers 10–15% weight loss with liver and cardiovascular benefits.

   2. Type 2 Diabetes Treatment:
   – Demonstrates HbA1c reduction, improved insulin resistance, and better glycemic profiles.

   3. NAFLD/NASH & Liver Health:
   – Up to 73% hepatic fat reduction suggests potential use in hepatic steatosis and non-alcoholic steatohepatitis.

   4. Cardiometabolic Risk Reduction:
   – Improves lipid profile, blood pressure, uric acid, and inflammatory markers—important for CV event risk modulation in obesity.

   5. Cognitive & Neurological Health:
   – Early animal data supports neurocognitive protection in diabetic models, potentially translating to improved brain outcomes in metabolic patients.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.